entity

O-GlcNAc

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about O-GlcNAc: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

4Connections
0Hypotheses
1Analyses
4Outgoing
0Incoming

Wiki Pages (20)

Knowledge base pages for this entity

Atypical Parkinsonism

disease · 6876 words

O-GlcNAcase (OGA) Inhibitor Landscape — Programs, Mechanisms, Companies

therapeutic · 3763 words

BIIB080 (MAPTRx) Antisense Oligonucleotide for Alzheimer's Disease

clinical · 3627 words

FNP-223 PROSPER Trial - Phase 2 in Progressive Supranuclear Palsy

clinical · 3559 words

Protein O-GlcNAcylation Pathway in Neurodegeneration

mechanism · 3298 words

Outgoing (4)

TargetRelationTypeStr
De Novo Nucleotide Synthesisregulatespathway0.95
NAD Productionregulatesprocess0.90
Glucose Metabolisminvolved_inpathway0.85
Glutamine Metabolisminvolved_inpathway0.85

Incoming (0)

SourceRelationTypeStr
No incoming edges

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
No targeting hypotheses

Mentioning Analyses (1)

Scientific analyses that reference this entity

Which tau PTMs are both disease-specific and druggable with selective small mole

neurodegeneration | 2026-04-13 | 2 hypotheses Top: 0.459

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
No papers found